Author:
Katsube Yurie,Tsujimoto Masayuki,Koide Hiroyoshi,Ochiai Megumi,Hojyo Ayako,Ogawa Kaori,Kambara Kengo,Torii Nao,Shima Daisuke,Furukubo Taku,Izumi Satoshi,Yamakawa Tomoyuki,Minegaki Tetsuya,Nishiguchi Kohshi
Funder
Ministry of Education, Culture, Sports, Science and Technology
Japan Society for the Promotion of Science
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference23 articles.
1. Sparreboom A, de Jonge MJ, de Bruijn P, Brouwer E, Nooter K, Loos WJ, van Alphen RJ, Mathijssen RH, Stoter G, Verweij J (1998) Irinotecan (CPT-11) metabolism and disposition in cancer patients. Clin Cancer Res 4:2747–2754
2. de Jong FA, van der Bol JM, Mathijssen RH, van Gelder T, Wiemer EA, Sparreboom A, Verweij J (2008) Renal function as a predictor of irinotecan-induced neutropenia. Clin Pharmacol Ther 84:254–262
3. Freyer G, Rougier P, Bugat R, Droz JP, Marty M, Bleiberg H, Mignard D, Awad L, Herait P, Culine S, Trillet-Lenoir V (2000) Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. Br J Cancer 83:431–437
4. Czock D, Rasche FM, Boesler B, Shipkova M, Keller F (2009) Irinotecan in cancer patients with end-stage renal failure. Ann Pharmacother 43:363–369
5. Fujita K, Sunakawa Y, Miwa K, Akiyama Y, Sugiyama M, Kawara K, Ishida H, Yamashita K, Mizuno K, Saji S, Ichikawa W, Yamamoto W, Nagashima F, Miya T, Narabayashi M, Ando Y, Hirose T, Sasaki Y (2011) Delayed elimination of SN-38 in cancer patients with severe renal failure. Drug Metab Dispos 39:161–164
Cited by
19 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献